University of California San Diego School of Medicine researchers report lesions of the appendix are being over diagnosed as invasive cancer.
Oncoceutics Inc. announced results from the first cohort of its phase II trial for patients with recurrent glioblastoma, which showed median overall survival in the first cohort of 17 patients two times that indicated in the current GBM patient literature.
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating pancreatic cancer, according to a study at MD Anderson Cancer Center.
A study at MD Anderson Cancer Center revealed new details about how enzyme acetyl-CoA synthetase 2 allows brain tumors to grow despite their harsh surroundings.
Martin Edelman, chair of hematology and oncology at Fox Chase Cancer Center, presented the results of a clinical study testing palbociclib, a drug used to treat breast cancer, in patients with squamous non-small cell lung cancer at the American Society of Clinical Oncology.
Clovis Oncology Inc. announced topline data from the confirmatory phase III ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival by investigator review in each of the three populations studied.
A study from the Austrian Breast & Colorectal Cancer Study Group indicates that women with metastasized breast cancer do not benefit from surgery performed prior to drug treatment. This could cause a paradigm shift in treatment of the disease.
Eisai Inc. announced results from the REFLECT study, a phase III trial evaluating lenvatinib (Lenvima), the company's multiple receptor tyrosine kinase inhibitor (including fibroblast growth factor receptors, for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. announced that data from the randomized phase III Alcanza clinical trial evaluating Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma was published in Lancet.
A meta-analysis of previously published cancer research showed no difference in five-year and 10-year survival rates between patients who underwent radical cystectomy and a bladder-preserving combined modality treatment plan.
